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Novel Therapies for Dyslipidemia
Olta Tafaj Reddy
Abstract
Multiple studies have shown a strong correlation between low-density lipoprotein 
cholesterol (LDL-C) concentration and development as well as progression of ath-
erosclerosis and cardiovascular disorders. Thus, the decrease of the LDL-C burden 
through lifestyle modification and/or pharmacological interventions unanimously 
demonstrated a decrease in cardiovascular events and mortality. To date, statins are 
considered the cornerstone of lipid-lowering therapy. The Cholesterol Treatment 
Trialists’ (CTT) Collaboration has shown consistency of treatment benefits across 
a wide patient population. However, new data are now revealing that a considerate 
patient population failed to achieve lipid goals solely on statins and a significant per-
centage cannot tolerate treatment. Therefore, extensive work has recently been done 
in generating novel LDL-C-lowering agents that would act through mechanisms 
different from statins. Among others, monoclonal antibodies to protein convertase 
subtilisin/kexin type 9 (PCSK9) and ezetimibe seem particularly promising. Both 
PCSK9 monoclonal antibodies and ezetimibe have shown to be well tolerated and 
very effective at lowering LDL-C.
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1. Introduction
Cardiovascular disease (CVD), which includes coronary heart disease (CHD) 
and strokes, is considered as a number one cause of morbidity and mortality 
worldwide. Together with hypertension, dyslipidemia is among the most prevalent 
risk factors leading to CVD. Thus, treatment of dyslipidemia is crucial in reducing 
CVD events and the morbidity and mortality associated with them. Studies in the 
last decade have confirmed a causal relationship between low-density lipopro-
tein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular diseases 
(ASCVD) [1]. LDL-C can be lowered by diet restriction and lifestyle changes or by 
various lipid-lowering therapies, among which statins (3-hydroxy-3-methylgluta-
ryl-coenzyme A [HMG-CoA] reductase inhibitors) are currently considered the 
cornerstone medication. Based on the 2018 guidelines published by the American 
College of Cardiology (ACC) and the American Heart Association (AHA), multiple 
recommendations have been made for patients with or at risk of developing cardio-
vascular disease [2].
Under certain circumstances, non-statin medications like ezetimibe and PCSK9 
inhibitors are found to be useful particularly in combination with statin therapy. 
Clinical trials pertaining to these novel therapies have shown great benefits with 
significant LDL-C-lowering potential and decrease in cardiovascular risk. These 
agents are generally well tolerated, but long-term safety and cost remain to be 
proven.
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2. PCSK9 inhibitors as cholesterol-lowering therapy
2.1 Genetics behind the discovery of PCSK9 inhibitors
PCSK9 gene was initially discovered as part of a search for members of the 
protein convertase family of serine proteases [3]. It was initially named as neural 
apoptosis-regulated convertase-1 (NARC1) due to its upregulation in apoptosis of 
primary cultures of cerebellar neurons. Subsequent studies classified it as a member 
of the proteinase K family of subtilases, and it was renamed as (proprotein conver-
tase subtilisin/kexin type 9 (PCSK9)). The gene mapped to chromosome 1p32 com-
prises 12 exons, and it is translated into a protein of 692 amino acids (NM-174936.3) 
and is mainly expressed in the liver [3]. Interestingly, the gene coding for PCSK9 
coincides with a region linked to dominant inheritance of hypercholesterolemia 
in American and French families who had no mutations in either LDL-R or APOB 
genes [4, 5]. Loss-of-function mutations in the later are the two main culprits that 
comprise 99% of cases with familial hypercholesterolemia (FH). Further genetic 
analysis of these index families identified a few rare heterozygous missense muta-
tions in PCSK9 gene, all coinciding with hypercholesterolemia [6]. Thus, PCSK9 is 
now recognized as the third gene causing FH and currently accounts for <1% of FH 
cases [7].
A crucial step in further understanding the role of this gene in cholesterol 
metabolism was achieved by Maxwell and Breslow, who showed that transgenic 
overexpression of PCSK9 in mice caused a FH-like phenotype due to increased 
intracellular degradation of the LDL-receptor (LDL-R) [8, 9]. This observation 
shed light into the physiological implication of PCSK9 gene in the lipid metabolism 
and dyslipidemia. It became clear that gain-of-function rather than loss-of-function 
mutations in PCSK9 lead to hypercholesterolemia. In the last decade, many disease-
causing mutations, occurring in various domains of the protein and leading to 
either increased transcription or impaired autocatalysis, have confirmed the above 
findings [10–13].
It was not until 2005 when studies in individuals with extremely low LDL-C lev-
els revealed some PCSK9 coding variants that were not seen in individuals with high 
levels of LDL-C. Some of these variants encoded truncated version of the protein 
that was clearly predicted to cause loss-of-function of PCSK9 [14, 15]. Mendelian 
randomization experiments clearly revealed that individuals with PCSK9 loss-of-
function variants had lifelong depressed LDL-C levels as well as reduced ASCVD 
risk [16]. In these initial studies, of 3363 blacks, 2.6% carried heterozygous PCSK9 
nonsense variants and were associated with 28 and 88% reductions in LDL-C and 
ASCVD risk, respectively. Of the 9524 white subjects examined, 3.2% had a PCSK9 
mutation and were associated with 15 and 47% reductions in LDL-C and ASCVD 
risk, respectively. The above results were then confirmed in subsequent larger 
cohort studies [17, 18].
Taken together, the findings in either gain-of-function or loss-of-function 
mutations in PCSK9 gene have provided very strong evidence for the potential 
pharmacological use of targeted reduction of PCSK9 protein. Additionally, studies 
of complete human knockouts of PCSK9 (biallelic loss-of-function mutations) 
revealed only isolated decreased LDL-C levels with no deleterious health complica-
tions [19, 20]. This supports the potential safety of pharmacologically targeting 
PCSK9. However, it is worth mentioning that carriers of PCSK9 loss-of-function 
mutations showed an increased risk of developing type 2 diabetes mellitus (T2DM) 
[21, 22]. This finding would suggest that a similar side effect may be encountered 
in potential pharmacological inhibitors of PCSK9 (an increase of T2DM has been 
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reported in statin drugs) [23]. However, no such association was found in clini-
cal trials with human monoclonal anti-PCSK9 [24]. An increased risk of T2DM 
was also observed in a phenome-wide association study performed in >337,000 
individuals with PCSK9 p.R46L mutation [25]. The same mutation was found to 
have a protective effect on hyperlipidemia, coronary heart disease (CHD), ischemic 
stroke, and cerebral infarction. No association with cataracts, heart failure, atrial 
fibrillation, or cognitive dysfunction was reported.
2.2 Mechanism of action of PCSK9 protein
PCSK9 is a serine protease involved in cholesterol metabolism. In the liver, 
it binds to the LDL-receptor (LDL-R), inducing intracellular degradation, thus 
reducing serum LDL clearance. Generally, PCSK9 molecule is absent allowing 
repeated recycling of the LDL-R receptor. One study also suggests that intracellular 
PCSK9 may be recycled so that a single molecule might contribute multiple times 
to receptor degradation [26]. Under physiological conditions, PCSK9 expression is 
very low compared to LDL-R, thus allowing continuous recycling of the receptor 
(Figure 1A). In the case of low intracellular levels of cholesterol, both LDL-R and 
PCSK9 are transcribed (Figure 1B). Once secreted in the plasma, PCSK9 serves 
as one of the many potential ligands for LDL-R. After endocytosis, LDL-R, LDL 
particle, and PCSK9 enter the lysosome. Once inside the lysosome, the LDL particle 
is degraded, whereas the LDL-R attached to PCSK9 fails to exit the lysosome, where 
it gets degraded and can no longer be recycled (Figure 1B) [10, 27, 28]. Using this 
intricate mechanism, PCSK9 would prevent overexpression of LDL-R and thus 
increase the intracellular cholesterol levels. On the other hand, in patients with 
elevated cholesterol levels, administering PCSK9 monoclonal antibodies would 
neutralize the PCSK9 molecules floating in the plasma, thus increasing LDL-R 
recycling and surface LDL-R (Figure 1C).
To better understand the action of PCSK9 inhibitors, we can correlate it with the 
pharmacological action of HMG-CoA reductase inhibitors (statins). Cholesterol is 
mainly synthetized in the liver via the mevalonate pathway, with HMG-CoA reduc-
tase being the rate-limiting enzyme in the process. The decrease in the intracellular 
cholesterol in the liver is sensed by sterol regulatory element-binding protein 2 
(SREBP2) which then increases the production of HMG-CoA reductase to promote 
the intracellular synthesis of cholesterol as well as increase LDL-R and PCSK9 
levels. As a result, statins will (1) decrease intracellular cholesterol production, (2) 
increase LDL-R expression on the hepatocytes, and (3) increase PCSK9 levels. This 
Figure 1. 
Under physiological conditions, PCSK9 expression is very low compared to LDL-R, thus allowing continuous 
recycling of the receptor (a). In the case of low intracellular levels of cholesterol, both LDL-R and PCSK9 are 
transcribed (b). In patients with elevated cholesterol levels, administering PCSK9 monoclonal antibodies would 
neutralize the PCSK9 molecules floating in the plasma, thus increasing LDL-R recycling and surface LDL-R (c).
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can explain why addition of anti-PCSK9 monoclonal antibodies can accentuate the 
lipid-lowering effect of statins.
2.3 Therapeutic rationale for PCSK9 inhibitors
Currently, statins are the first-choice agents to reduce high blood cholesterol 
which is considered one of the main risk factors for cardiovascular disease (CVD). 
Cholesterol Treatment Trialists’ (CTT) Collaboration as well as other clinical trials 
showed that primary prevention with statins reduced all-cause mortality, reduced 
combined fatal and nonfatal stroke, reduced revascularization rate, and improved 
patient quality of life [29, 30]. Statin prescription is not associated with serious 
harm and is considered to be cost-effective [31]. That said, in the last decade, many 
patients have reported more and more severe side effects particularly with high-
intensity statin therapy [32]. Additionally, certain patient populations (familial 
hypercholesterolemia) are at particular high risk for cardiovascular events. The risk 
can be attributed to the complexity of the underlying disease, and sole treatment 
with statins may be insufficient.
Familial hypercholesterolemia: Familial hypercholesterolemia (FH) is a 
complex genetic disorder characterized by high LDL-C levels and early incidence 
of ASCVD [33]. There are two forms of FH: a heterozygous and homozygous one 
with a prevalence of 1 in 250 and 1 in 250,000, respectively [34]. The disorder is 
characterized by high-serum LDL-C concentration, xanthomas including Achilles 
tendon thickening, and premature coronary artery disease (CAD). In FH patients, 
the prevalence of CAD is extremely high, and its age of onset is 15–20 years earlier 
than usual. Thus, early diagnosis and appropriate treatment are crucial.
Statin intolerance: Statin intolerance is defined as an inability to take statin 
because of reported side effects. It is classified as complete (inability to tolerate any 
statin at any dose) or partial (inability to tolerate high doses of statin). The most 
common reported adverse effect is muscle pain due to myopathy and rhabdomyoly-
sis in severe cases. Though rare, rhabdomyolysis can be serious if not detected and 
treated early. An increased risk of type 2 diabetes has also been reported, particu-
larly with high-dose statins [35]. Two recent meta-analyses observed a 9% increased 
risk for incident diabetes associated with statin therapy, with little heterogeneity 
between studies. Hemorrhagic stroke also appears to be increased by statin therapy, 
although estimates are imprecise. However, overall stroke events were reduced, 
indicating a net benefit.
2.4 Anti-PCSK9 monoclonal antibodies and the cardiovascular outcome studies
Multiple studies were performed to investigate the cardiovascular effect of 
the anti-PCSK9 monoclonal antibodies. The Further Cardiovascular Outcomes 
Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial, 
a randomized, double-blinded, placebo-controlled trial published in 2017, is 
currently considered one of the landmark studies in the efficacy of anti-PCSK9 
monoclonal antibodies [36]. The aim of the study was to understand whether 
evolocumab (anti-PCSK9 monoclonal antibody) which lowers LDL-C levels by 69% 
can prevent cardiovascular events. This trial included 27,564 patients with athero-
sclerotic cardiovascular disease and LDL-C levels of ≥70 mg/dl while on maximally 
tolerated statin therapy. Patients were then randomly assigned to either evolocumab 
(140 mg every 2 weeks or 429 mg monthly) or placebo. The primary end point of 
the study was the composite of cardiovascular death, myocardial infarction, stroke, 
hospitalization for unstable angina, or coronary revascularization. The secondary 
end point was the composite of cardiovascular death, myocardial infarction, or 
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stroke. The median duration of follow-up was 2.2 years. Inhibition of PCSK9 with 
evolocumab on a background of statin therapy lowered LDL-C levels to a median of 
30 mg/dl. Addition of evolocumab to statin therapy significantly reduces the risk of 
cardiovascular events, with a 15% reduction risk of primary composite and a 20% 
reduction risk of the secondary composite outcomes. Based on this study, PCSK9 
inhibitor therapy should be considered for ASCVD risk reduction in patients with 
stable ASCVD, particularly in those with additional risk factors, on maximally 
tolerated statin therapy, with on-treatment LDL-C ≥70 mg/dl or non-HDL-C 
≥100 mg/dl. In the same FOURIER trial, similar recommendations but with a lower 
level of evidence can also be applicable to patients with progressive ASCVD (addi-
tional diagnosis of MI or nonhemorrhagic stroke).
2.5 Anti-PCSK9 monoclonal antibodies in patients with statin intolerance
There is currently no universally accepted definition for statin intolerance. 
Previous studies have confirmed statin-related muscle side effects; however more 
needs to be done to accurately address the issue. That said, statin intolerance in 
individuals with a history of CVD is a challenge to a clinician. According to the lat-
est National Lipid Association (NLA) recommendations, PCSK9 inhibitors may be 
considered to reduce LDL-C in selected very-high-risk patients who are classified as 
statin-intolerant, in the presence of additional LDL-C-lowering therapies [37]. The 
quality of evidence for such a recommendation is low.
2.6 Anti-PCSK9 monoclonal antibodies in patients with severe 
hypercholesterolemia
Severe hypercholesterolemia is defined as LDL-C ≥190 mg/dl. The majority of 
these patients have polygenic hypercholesterolemia attributed to multiple, unde-
fined genetic factors. Familial hypercholesterolemia (both heterozygous and homo-
zygous) is due to defined mutations yet less commonly encountered. Regardless of 
the etiology, long-term risk for cardiovascular diseases in all these patients is very 
high. However, studies have shown that particularly patients with clinically defined 
FH have a greater risk for cardiovascular events despite being on maximum dose of 
statins. Studies in patients with heterozygous familial hypercholesterolemia who 
received PCSK9 inhibitors (either alirocumab or evolocumab) revealed significant 
additional LDL-C reduction.
Based on the current data, the National Lipid Association is recommend-
ing addition of PCSK9 inhibitors in patients with LDL-C ≥190 mg/dl with 
additional risk factors or genetic confirmation of FH on maximally tolerated 
statin ± ezetimibe.
2.7 Intravascular ultrasound trial
In order to determine the effects of PCSK9 inhibitors (evolocumab) on progres-
sion of coronary atherosclerosis in statin-treated patients, the Global Assessment of 
Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound 
(GLAGOV) multicenter, double-blind, placebo-controlled, randomized clinical 
trial was conducted [38]. In this trial 968 patients with angiographic coronary 
disease were studied. These patients were randomized to receive monthly 420 mg 
evolocumab or placebo via subcutaneous injection for 76 weeks, in addition to 
moderate- or high-intensity statins. In this trial, the primary efficacy was the 
change in percent atheroma volume from baseline to week 78, measured by serial 
intravascular ultrasonography (IVUS) imaging. Secondary efficacy was measured 
Dyslipidemia
6
in normalized total atheroma volume and patients demonstrating plaque regression. 
Interestingly, IVUS showed atherosclerosis regression during 18 months of therapy 
in patients treated with the combination of evolocumab and statins and absence of 
regression in patients treated with statin alone. Additionally, the evolocumab group 
showed a significant reduction in percent atheroma volume as well as total ath-
eroma volume (−0.95%, p < 0.01, between group difference, −4.9 mm3, p < 0.01, 
respectively). Taken together, PCSK9 inhibitors produce additional benefits on 
coronary disease progression in statin-treated patients.
2.8 Efficacy and safety of anti-PCSK9 monoclonal antibodies
The most recent study to evaluate the effects of alirocumab on the occurrence 
of cardiovascular events in patients who have experienced an acute coronary 
syndrome (ODYSSEY OUTCOMES) suggested a reduction in mortality with ali-
rocumab in patients after acute coronary syndrome [39].Based on the results from 
multiple trials, alirocumab reduced the risk of all-cause mortality: 6 fewer deaths 
per 1000 patients treated (RR, 0.82; 95% CI 0.72–0.95). No reduction in cardio-
vascular mortality was observed (RR, 0.87; 95% CI, 0.73–1.02) [40]. On the other 
hand, trials of evolocumab did not show a reduction in either all-cause or cardio-
vascular mortality (RR, 0.91; 95% CI, 0.57–1.44 and RR, 1.04; 95% CI, 0.88–1.24, 
respectively). Taken together, PCSK9 inhibitors did not reduce the risk of all-cause 
or cardiovascular mortality.
Both alirocumab and evolocumab reduced the risk of myocardial infarction, 
stroke, and coronary revascularization. Alirocumab, but not evolocumab, reduced 
stable angina hospitalization, and neither drug reduced heart failure.
Regarding the safety of anti-PCSK9 monoclonal antibodies (alirocumab 
and evolocumab), all phase 2 and 3 studies have demonstrated excellent safety 
profile [41]. The most commonly reported adverse effect has been injection site 
reaction [42]. As part of the safety analysis, fat-soluble vitamin concentrations 
(A, D, E, K) were measured. Compared to placebo, no change in the levels of 
any of these vitamins was reported. Additionally, no increase in neurocognitive 
events, new-onset or worsening diabetes, muscle-related events, or myalgia has 
been noted [43].
Bococizumab has been excluded from most of these studies as the drug is no 
longer available after the cessation of development by the manufacturer due to high 
rates of neutralizing antibody formation and subsequent loss of therapeutic efficacy 
(SPIRE trial) [44].
3. Ezetimibe as cholesterol-lowering therapy
Since the early 1990s when statins were initially introduced, several large clinical 
trials have highlighted the benefits of their use with beneficial effects above and 
beyond lipid lowering [45]. Statins are currently the cornerstone of hyperlipidemia 
treatment. However, due to safety concerning high-dose therapy as well as residual 
risk of CVD especially in high-risk patients, additional lipid-modifying therapies 
have emerged in the last decades.
Ezetimibe reduces absorption of cholesterol from the brush border of the small 
intestine by targeting the Niemann-Pick C1-like 1 (NPC1L1) protein (Figure 2) 
[46, 47]. Genetic studies have shown that polymorphisms affecting NPC1L1 are 
associated with lower levels of LDL cholesterol and a lower risk of cardiovascular 
diseases [48]. A decrease in cholesterol absorption results in a decrease of total 
cholesterol, triglycerides, and LDL cholesterol and an increase in HDL cholesterol.
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It was FDA-approved in 2002 as an agent to treat people with hyperlipidemia. 
Ezetimibe given as monotherapy leads to an LDL reduction of approximately 20%. 
When added to statins, ezetimibe reduces LDL cholesterol levels by an additional 
23–24% on average [49, 50]. The Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVE-IT) was then conducted to understand if further 
lowering of the LDL-C levels by statin-ezetimibe dual therapy leads to clinical 
benefit [51]. In this trial they studied the effect of ezetimibe combined with simvas-
tatin, as compared with that of simvastatin alone, in stable patients who had an acute 
coronary syndrome and whose LDL cholesterol values were within the guideline 
recommendations. The primary end points were death from cardiovascular disease, 
a major coronary event, or nonfatal stroke, assessed from the time of randomiza-
tion until the first occurrence of one of the events. The combination of simvastatin 
and ezetimibe resulted in additional lowering of LDL-C levels as well as lower risk 
of cardiovascular event. A reduction of cholesterol levels of 12.8 mg per deciliter 
correlated with a proportionally 7.2% lower rate of major vascular events, providing 
further evidence for a relationship between lower lipid and improved outcomes.
Multiple statin trials including the CTT collaboration have shown clinical ben-
efits when LDL cholesterol was lowered to progressively lower levels. It was on the 
basis of these trials that a LDL-C of <70 mg per deciliter has been recommended for 
patients with acute coronary syndrome. Data from the IMPROVE-IT trial support 
the previous finding and show a direct evidence between further lipid lowering 
and improved outcomes [51]. Additionally, this trial provides evidence, for the 
first time, that a non-statin lipid-lowering agent can reduce cardiovascular risk by 
lowering LDL-C and that statins are not the only beneficiary drugs in hyperlipid-
emia. The American College of Cardiology recommends consideration of ezetimibe 
therapy in addition to maximally tolerated statin therapy for both primary and 
secondary prevention in patients who have not achieved target reduction in their 
LDL-C by maximally tolerated statin therapy alone.
3.1 Administration, side effects, and contraindications of ezetimibe
Ezetimibe is currently marketed as a monotherapy under the trade name of 
Zetia, as well as in combination with a statin such as Vytorin and Liptruzet. It has a 
Figure 2. 
Ezetimibe reduces absorption of cholesterol from the brush border of the small intestine by targeting the 
Niemann-Pick C1-like 1 (NPC1L1) protein. In the liver, HMG-CoA reductase (statins) promotes the 
intracellular synthesis of cholesterol as well as increases LDL-R and PCKS9 levels. PCSK9 monoclonal 
antibodies would neutralize the PCSK9 molecules floating in the plasma, thus increasing LDL-R recycling and 
surface LDL-R in the liver.
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half-life of 22 hours, and it can be administered at 10 mg daily. It can be taken at the 
same time as fenofibrates or statins, but it is recommended to take it at least 2 hours 
before or 4 hours after taking bile acid sequestrants.
Based on current studies, very few side effects to ezetimibe have been 
reported, most common being headache, runny nose, and sore throat [52]. 
Rhabdomyolysis has been reported only in combination with statin therapy and 
rarely with monotherapy. Due to its daily dosing and limited side effects, ezeti-
mibe is considered a safer drug with no compliance issues. Contraindications to 
its use include hypersensitivity to possible ingredients of the formulation. It is not 
recommended in patients with moderate to severe hepatic impairment but can be 
administered in patients with renal impairment without any need for dose adjust-
ment. Liver function tests need to be performed only if it is administered with a 
statin. It is worth mentioning that patients taking ezetimibe with cyclosporine are 
at an increased risk of ezetimibe toxicity as it can result in 2.3–12-fold increase 
in exposure [53]. In these cases, cyclosporine concentrations should be closely 
monitored.
3.2  Ezetimibe versus anti-PCSK9 monoclonal inhibitor (evolocumab) as add-on 
therapy for secondary prevention of cardiovascular events
When results from trials of ezetimibe (IMPROVE-IT) and PCSK9 inhibitors 
(FOURIER RCT) are compared in regard to secondary prevention of cardiovas-
cular events in patients with ASCVD and type 2 diabetes, evolocumab (PCSK9 
inhibitor) seems to be more effective [54]. Interestingly, as of December 2018, 
the annual cost of evolocumab is $6540 and $88 for ezetimibe. From a healthcare 
cost standpoint, ezetimibe has a significantly lower cost and may be considered 
a preferred add-on therapy for these patients. The difference in avoiding car-
diovascular events between the two therapies is negligible compared with the 
significant difference in the drug costs. However, a randomized controlled trial 
(RCT) comparing evolocumab and ezetimibe would be necessary to evaluate and 
compare the effectiveness of these two drugs. Additionally, long-term effects of 
these novel drugs in reducing the cardiovascular events in patients with ASCVD 
and type 2 diabetes will be needed.
4. Conclusions
Dyslipidemia is a major risk factor for both fatal and nonfatal CVD. Lowering 
cholesterol levels particularly LDL-C, through lifestyle modifications as well 
as pharmacological interventions, is crucial for CVD risk reduction. Currently, 
statins are the cornerstone medication for treatment and primary prevention of 
hypercholesterolemia. Studies have shown that benefits from statins outweigh 
any possible adverse effects. However, as the intensity of statin therapy increases, 
intolerance to their use becomes more prominent. Additionally, high-risk 
patients on maximally tolerated statins may benefit from novel LDL-C-lowering 
therapies. Clinical trials have provided evidence that these novel drugs such 
as PCSK9 inhibitors or ezetimibe can successfully lower LDL-C in levels and 
contribute in lowering cardiovascular events in high-risk patients with elevated 
LDL-C on maximally tolerated statins. Both ezetimibe and PCSK9 inhibitors 
have demonstrated a modest absolute ASCVD risk reduction and good safety 
profiles. However, given cost considerations particularly for PCSK9 inhibitors, 
healthcare providers will need to carefully consider the subgroup of patients 
benefiting the most from their use.
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